Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises founder and major shareholders on the sale of Dynamic Code AB
Mandate

Vinge advises founder and major shareholders on the sale of Dynamic Code AB

September 17, 2021 M&A

Vinge is advising the founder and major shareholders in connection with the sale of Dynamic Code AB.

Dynamic Code develops and sells self-sampling kits based on DNA technology. The samples are analysed in Dynamic Code’s own lab and the test results are obtained through a code online. Care and treatment is thereafter offered via digital health care providers and Dynamic Code has, based on that, been able to create a complete chain of health care through its e-health platform.

Closing of the transaction is subject to due diligence and that shareholders representing 95 per cent of all shares in Dynamic Code adhere to the share transfer agreement.

The Vinge team includes Anna Edström, Magnus Hedsund and Niklas Törnell.

 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024